Company: TELO
Filing Date: 2025-11-20
Form Type: PREM14A
Source: 0001493152-25-024463
Chunk: 79

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-20
Form: PREM14A
Chunk 79
---
 treatment of certain types of high-risk, early-stage breast cancer. The most recent expansion 
 was in March 2023.                                                                                                                        |
| ● | NovartisAG                                                                                                                                
 (SWX:NOV) – NOV has developed Kisqali, also a CDK4/6 inhibitor, used in HR+/HER2- breast cancer.                                          |

| 45 |

Treatment-Market for Age-Related Macular Degeneration (AMD)

Telomir-1 also has shown the potential within zebrafish to treat age-related macular degeneration (AMD), a medical condition resulting in may result in blurred or no vision in the center of the visual field.

The global market for AMD treatment is substantial and growing. According to one source, the global market was valued at approximately US$9.9 billion in 2024, with a projected rise to about US$15.8 billion by 2033.In Europe the market is forecast to grow at a compound annual growth rate (CAGR) around 6-8%, while in the Asia-Pacific region, higher growth rates (around 9.5% or more) are anticipated thanks to rising ageing populations and expanding healthcare access.

Beyond numbers, key trends are emerging:

| ● | A                                                                                                       
 shift toward newer therapies (e.g., gene therapy, stem cell approaches) though many remain              
 early-stage.                                                                                            |
| ● | Increased                                                                                               
 uptake of advanced diagnostics and delivery approaches (e.g., longer-interval dosing, sustained-release 
 injections) particularly in more developed markets.                                                     |
| ● | Growing                                                                                                 
 pressure in cost and reimbursement in many non-US markets as payers push for value given                
 the high cost of anti-VEGF and other therapies.                                                         |

Regional variations & opportunities

Europe: Europe is a mature market with strong healthcare infrastructure, established reimbursement systems, and a large elderly cohort. Reports show Europe at a market size of around US$3.8 billion in 2025 for AMD treatment, with a forecast CAGR ~8.2%. Because access is generally better and regulatory approval pathways well defined (via the European Medicines Agency), the pace of new therapy adoption is relatively strong.

Asia-Pacific: This region is seen as a high-potential growth area. In some estimates, Asia-Pacific is projected to grow at ~9½ % CAGR through 2030. Key factors include rapidly ageing populations in countries such as Japan, China, India; increasing demand for eye care services; improved diagnostics; rising healthcare